Neoadjuvant and adjuvant strategies for chemoradiation

Area of Science:

• Oncology
• Surgical Oncology
• Radiotherapy

Background:

• Evidence suggests adjuvant therapy improves outcomes for resectable pancreatic cancer.
• Current adjuvant options include chemotherapy or combined chemoradiotherapy, but data are controversial.
• A standardized global treatment protocol is lacking, emphasizing the need for precise patient selection.

Purpose of the Study:

• To review current evidence on adjuvant therapy for resectable pancreatic cancer.
• To highlight ongoing research focusing on novel therapeutic agents and improved radiotherapy techniques.
• To introduce a multicentric European trial evaluating chemoradiotherapy in pancreatic head cancer.

Main Methods:

• Review of phase III clinical trials and available data on adjuvant treatment modalities.
• Focus on chemotherapy (gemcitabine), targeted therapies (EGFR-MoABs, anti-angiogenic drugs), and advancements in radiooncology.
• Description of a current European Organization for Research and Treatment of Cancer (EORTC) trial for R0-resected pancreatic head cancer.

Main Results:

• Heterogeneous data exist regarding the efficacy of different adjuvant approaches.
• Chemotherapy alone and multimodal therapy are potential options, with ongoing debate.
• Recent advances in radiotherapy offer improved safety and efficacy profiles.

Conclusions:

• Adjuvant therapy is a promising strategy for resectable pancreatic cancer.
• Individualized patient selection is key to optimizing treatment outcomes.
• Further research, including multicenter trials, is essential to establish a definitive standard of care.